We await further updates then ,
Further updates will be provided as information is released by the relevant agencies.
All clinical data to date on DMX-200 demonstrates an exceptionally strong safety profile, with no serious adverse events related to the drug reported, and that the DMX-200 clinical benefit has outweighed any risks to date.
The positive signals suggest that treatment with DMX-200 may indeed result in clinically meaningful improvements in kidney function in FSGS patients.
I'm full to the gunnels...
Hope you have a relaxing weekend with friends and family , NZT
Ann: DMX-200 Remains Eligible for Accelerated Approval, page-15
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.0¢ |
Change
-0.005(1.08%) |
Mkt cap ! $253.1M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 49.0¢ | 45.5¢ | $1.771M | 3.761M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 34765 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 26998 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |